SCC
NKGNW

Spring Creek Capital’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

Spring Creek Capital’s Portfolio NKGNW Stock Details NKGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-92,040
Closed -$56K – 117
2022
Q1 		$56K Hold
92,040
– – ﹤0.01% 542
2021
Q4 		$106K Hold
92,040
– – ﹤0.01% 464
2021
Q3 		$107K Buy
+92,040
New +$115K 0.01% 391

Other funds holding NKGNW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Spring Creek Capital's NKGNW Position: Q2 2022 in Review

Spring Creek Capital sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q2 2022, closing a stake of 92,040 shares — an estimated $56K sold.

Spring Creek Capital first reported a position in NKGNW in Q3 2021 and held it in 3 quarters. The position peaked at $107K in Q3 2021. 35 funds tracked by Wall St. Rank hold NKGNW as of Q2 2022.

  • Spring Creek Capital reported no remaining NKGen Biotech, Inc. Warrants position as of Q2 2022 after selling out during the quarter.
  • Spring Creek Capital sold 92,040 NKGen Biotech, Inc. Warrants shares in Q2 2022, an estimated $56K.
  • Spring Creek Capital first reported a position in NKGen Biotech, Inc. Warrants in Q3 2021 and held it in 3 quarters.
  • Spring Creek Capital's NKGen Biotech, Inc. Warrants position peaked at $107K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.